User:Mr. Ibrahem/Trametinib

Trametinib, sold under the trade name Mekinist, is a medication used to treat certain types of melanoma, non-small cell lung cancer, and anaplastic thyroid cancer. Specifically it is used for cancers with the BRAF V600E mutation. It is taken by mouth.

Common side effects include rash, diarrhea, tiredness, swelling, nausea, and fever. Other side effects may include new cancers, bleeding, colitis, blood clots, and heart failure. Use during pregnancy may harm the baby. It is a MEK inhibitor and blocks both MEK1 and MEK2.

Trametinib was approved for medical use in the United States in 2013 and Europe in 2014. In the United Kingdom a month of medication costs the NHS about £4,800 as of 2021. This amount in the United States costs about 13,200 USD.